MonobactamsLucas Cruz, Brasil

Chromobacterium violaceum

Enzymatic

inactivation

Antibiotic efflux

Modification of the

target receptor

Difficulty of

penetrating the

cell

Resistance

Spectrum of Action:

Aerobic Gram-negatives

IV ou IM

Pharmacokinetics

Drug Interactions

Clinical use

Urinary Tract Infection

Gram-negative sepsis

Cystic

Fibrosis

1 g, 8/8 or 12/12H

Via IV

500mg, 12H

2g, de 6/6h

30mg/kg 12, 8 our6/6h

Dose

Side effects

Comercial presentation

1. Aztreonam acts only against gram-negative aerobiic

2.Is resistant to beta-lactamases

3. Few side effects

4. It is useful in the treatment of patients allergic to penicillin

Don’t

forget:

Bibliografic References:

• TAVARES, W. Antibióticos e quimioterápicos para o clínico/Walter Tavares. 2ª ed. Ver. e atual. São Paulo: Editora Atheneu, 2009. p. 210 a 212.

• VINKS, A. A.. et al. Pharmacokinetics of Aztreonam in Healthy Subjects and Patients with Cystic Fibrosis and Evaluation of Dose-Exposure Relationships Using Monte Carlo Simulation. 2007. American Society for microbiology. Disponível em:http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2043218/?tool=pubmed/ Acessado em: 04 de dezembro de 2010.

• WALKININE, Y. FDA Approves Inhaled Aztreonam for Cystic Fibrosis. 2010. MedScape. Disponível em: http://www.medscape.com/viewarticle/717553 Acessado em: 05 de dezembro de 2010.